Pulmatrix (NASDAQ:PULM) Announces Earnings Results

by · The Cerbat Gem

Pulmatrix (NASDAQ:PULM – Get Free Report) posted its quarterly earnings data on Friday. The biotechnology company reported ($0.32) EPS for the quarter, FiscalAI reports.

Pulmatrix Stock Down 1.6%

PULM traded down $0.02 during midday trading on Friday, reaching $1.25. The company had a trading volume of 17,492 shares, compared to its average volume of 31,072. The business has a 50-day moving average of $1.56 and a two-hundred day moving average of $2.73. The company has a market cap of $4.56 million, a P/E ratio of -0.89 and a beta of 1.94. Pulmatrix has a 1 year low of $1.16 and a 1 year high of $9.37.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new position in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pulmatrix presently has an average rating of “Sell”.

Read Our Latest Research Report on Pulmatrix

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).

Further Reading